FGFabrícia Gimenes

Fabrícia Gimenes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabrícia Gimenes has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of vitamin D3 (cholecalciferol) supplementation in patients with HIV

    by Elaine Cristina Birssi, Monica Micheli Alexandre, Fabricia Gimenes, Samara Felicia da Silva, Juliana Cogo, Daniela de Cássia Faglioni Boleta-Ceranto, Aurea Regina Telles Pupulin, Giuliana Zardeto

    Human immunodeficiency virus (HIV) infection remains a global public health problem that affects thousands of people annually. One of the main comorbidities identified in HIV-positive patients undergoing antiretroviral treatment is insufficiency of vitamin D, a key hormone involved in physiological and metabolic processes in the human body. This review aimed to evaluate the importance of vitamin D3 supplementation in HIV-positive patients with serum concentrations below the recommended limits. The literature search included indexed articles published from 2015 to 2023. The article search strategy included the databases of the National Library of Medicine (PUBMED) and Scientific Electronic Library Online (SCIELO). Non-acquired immunodeficiency syndrome (AIDS)-related opportunistic pathologies are the main causes of morbidity and mortality despite the efficacy of antiretroviral therapy. Several studies have shown that hypovitaminosis D is diagnosed during HIV progression and may be associated with reduced survival rates, highlighting the importance of measuring vitamin D serum levels and providing exogenous vitamin D3 supplementationif needed for these patients. Several studies have pointed out the benefits of vitamin D3 supplementation in HIV-infected patients, independent of antiretroviral treatment, such as the reduction of inflammatory processes and mediators related to bone renewal, increase in CD4 + T lymphocyte count, and increase in antibacterial response against invading microorganisms. Given the importance of this disease worldwide, which is associated with a high number of deaths, there is justification for intensifying and deepening research on the potential and significant role of vitamin D3 supplementation.

  • Open Access

    Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer

    by Larissa Bahls, Roger Yamakawa, Karina Zanão, Daniela Alfieri, Tamires Flauzino, Francieli Delongui, André De Abreu, Raquel Souza, Fabrícia Gimenes, Edna Reiche, et al.

    Only a small proportion of women who are exposed to infection with high-risk human papillomavirus (HR-HPV) progress to persistent infection and develop cervical cancer (CC). The immune response and genetic background of the host may affect the risk of progression from a HR-HPV infection to lesions and cancer. However, to our knowledge, no studies has been conducted to evaluate the relationship between variability of human leukocyte antigens (HLA) genes and serum cytokine expression in this pathology. In the current study, we examined the associations of HLA alleles and haplotypes including Class I (HLA-A, -B and -C) and II (HLA-DRB1, -DQA1 and -DQB1) with serum levels of cytokines interleukin (IL)-6, tumor necrosis factor-α (TNF-α), IL-10 and IL-17 as well as risks of HPV infections, lesions and CC among admixed Brazilian women. HLA polymorphisms were associated with an increased risk or protection from HPV, lesions and CC. Additionally, we demonstrated a potential association of a HLA class I haplotype (HLA-B*14-C*08) with higher IL-10 cytokine serum levels in cervical disease, suggesting an association between HLA class I and specific cytokines in cervical carcinogenesis. However, larger studies with detailed HPV types coupled with genetic data are needed to further evaluate the effects of HLA and CC by HPV genotype.


  • Open Access

    EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON VAGINAL Candida spp. ISOLATION IN HIV-INFECTED COMPARED TO HIV-UNINFECTED WOMEN

    by Silvia de Souza Dantas Alczuk, Patrícia de Souza Bonfim-Mendonça, Sheila Cristina Rocha-Brischiliari, Cristiane Suemi Shinobu-Mesquita, Helen Priscilla Rodrigues Martins, Fabrícia Gimenes, André Luelsdorf Pimenta de Abreu, Maria Dalva de Barros Carvalho, Sandra Marisa Pelloso, Terezinha Inez Estivalet Svidzinski, et al.

    Vulvovaginal candidiasis (VVC) in HIV-infected women contributed to the impairment of their quality of life. The aim of this study was to evaluate the effect of highly active antiretroviral therapy (HAART) use on the vaginal Candida spp. isolation in HIV-infected compared to HIV-uninfected women. This cross-sectional study included 178 HIV-infected (HIV group) and 200 HIV-uninfected women (control) that were studied at the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/AIDS of the city of Maringá, Brazil, from April 1 to October 30, 2011. The yeasts were isolated and identified by phenotypic and molecular methods. The in vitro antifungal susceptibility to fluconazole, itraconazole, nystatin and amphotericin B was tested by the reference microdilution method. Higher frequencies of total vaginal Candida spp. isolation were found in the HIV-infected group than in the control group. However, both groups showed a similar frequency of colonization and VVC. Although C. albicans was the most frequent and sensitive to azolics and polyenes in both HIV-infected and uninfected women, the emerging resistance of C. glabrata to amphotericin B in the HIV-infected women was observed. Although higher frequency of vaginal Candida spp. isolation had been observed in the HIV-infected than in HIV-uninfected women, colonization and VVC showed similar frequency in both groups, indicating that HAART appears to protect against vaginal colonization and VVC.


  • Open Access

    Risk factors for cervical HPV infection and genotypes distribution in HIV-infected South Brazilian women

    by Sheila C Rocha-Brischiliari, Fabrícia Gimenes, André L P de Abreu, Mary M T Irie, Raquel P Souza, Rosangela G Santana, Angela A F Gravena, Maria D de B Carvalho, Marcia E L Consolaro, Sandra M Pelloso

    Background: Human Papillomavirus (HPV) infection is particularly burdensome for women infected with human immunodeficiency virus (HIV), which increases their risk of developing cervical lesions and cancer (CC). We conducted a molecular study of the distribution of cervical HPV genotypes and the risk factors for this infection in HIV-infected Brazilian women. Findings: Cervical and endocervical samples for Papanicolaou screening and HPV detection were collected from 178 HIV-infected women using highly active antiretroviral therapy (HAART) of Maringá city/Brazil. Risk factors were assessed using a standardized questionnaire, and the data regarding to HIV infection from medical records. HPV was detected by polymerase chain reaction (PCR), and genotyping using PCR-restriction fragment length polymorphism analysis. HIV infection was well controlled, but women with a current CD4+ T lymphocyte count between 200–350 cells/mm3 (37.6%) had a two-fold greater risk of HPV infection than those with > 350 cells/mm3 (26.4%). HPV was associated with parity ≥3, hormonal contraceptive use and current smoker. HPV infection occurred with high frequency (46.6%) but a low frequency of cervical abnormalities was detected (7.30%), mainly low-grade squamous intraephitelial cervical lesions (LSIL) (84.6%). A high frequency of multiple HPV infections was detected (23.0%), and the most frequent HPV genotype was HPV-72 (6.7%), followed by −16, -31 and -51 (6.14% each). Conclusions: We showed that HAART use does not protect HIV-infected women from HPV, but appear to exert some protection against cervical lesions development. This study provides other important information about risk factors and cervical HPV in HIV-infected women, which can contribute to planning protocols.


  • Open Access

    Differences in the mutation of the p53 gene in exons 6 and 7 in cervical samples from HIV- and HPV-infected women

    by Raquel P Souza, Fabrícia Gimenes, André Lp de Abreu, Sheila C Rocha-Brischiliari, Maria Db de Carvalho, Érika C Ferreira, Marcelo G Bonini, Sandra M Pelloso, Marcia EL Consolaro

    Background: Human Papillomavirus (HPV) infection is a serious problem for human immunodeficiency virus (HIV)-infected women, increases their risk of cervical lesions and cancer. In cervical carcinogenesis, mutations in the p53 gene occur most frequently within exons 5–8. To our knowledge, no previous studies have analyzed mutations in exons 5–8 of the p53 gene in HIV- and HPV-infected women. In our study, we verified these mutations in women with and without cervical abnormalities. Findings: The study included 160 women, divided into three groups: (1) 83 HPV- and HIV-infected women (HIV group); (2) 37 HPV-infected/HIV-uninfected (control group); and (3) 40 normal cytology/DNA-HPV negative/HIV-uninfected women (negative control p53 reactions). HPV-DNA was detected using polymerase chain reaction (PCR) and genotyping by PCR-restriction fragment length polymorphism analysis. Using primers for exons 5–8, the mutation of the p53 gene was verified by PCR-single strand conformational polymorphism. The total mutation of the p53 gene in exons 5–8 was not significantly associated with the HIV and control groups. The mutations in exon 7 were the highest in the HIV group (43.8%) and in exon 6 in the control group (57.2%) (p = 0.0793) suggesting a tendency toward differential mutation in exon 7 in the HIV group. Conclusions: Our study provides preliminary evidence that the mutation in exon 7 might be an important differentiating factor for cervical carcinogenesis in HIV-infected women. This aspect deserves an additional cross-sectional and longitudinal study using a larger sample size with a higher number of High-grade squamous intraephitelial lesion (HSIL) to observe the evolution of cervical lesions.


  • Open Access

    A review of methods for detect human Papillomavirusinfection

    by André L P Abreu, Raquel P Souza, Fabrícia Gimenes, Marcia E L Consolaro

    Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops over a long period through precursor lesions, which can be detected by cytological screening. Although this screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of women with HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related biomarkers, a variety of methods are being developed for these purposes. This review summarizes current knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a high risk of progression to CC.